AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Transcranial Magnetic Stimulation for Nicotine Dependence: An Effectiveness-Implementation Trial

RecruitingPhase 4Ages 18 Years - 70 YearsAllCentre for Addiction and Mental Health
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Tobacco smoking is the leading preventable cause of morbidity and mortality worldwide. However, currently available treatments, including standard pharmacotherapy and behavioural support, are limited in their efficacy, tolerability, and acceptability by patients. Additionally, tobacco use is substantially higher in individuals with comorbid mental illness, constituting a particularly vulnerable population. As such, the development of multiple evidence-based treatments for smoking cessation is of upmost importance. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain-based approach in which alternating magnetic fields are applied to the scalp to induce electrical currents in cortical tissue. As it can modulate neural circuits implicated in neuropsychiatric disorders, it is a promising brain-based approach in the treatment of substance use disorders. Recently, a dee

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: Patient Participants: The patient participant must meet all the inclusion criteria to be eligible for this study: 1. Able to provide informed consent. 2. Age 18-70. 3. Self-reported daily tobacco cigarette consumption. 4. Meet DSM-5 criteria for a psychiatric disorder that includes one of the following: mood disorders (e.g. major depressive disorder, bipolar disorder), anxiety disorders (e.g. panic disorder, social anxiety disorder), psychotic disorders (e.g. schizophrenia), posttraumatic stress disorder, obsessive compulsive disorders, or other substance use disorders (e.g. alcohol use disorder) as determined by the Structured Clinical Interview for DSM-5 Disorders, Research Version (SCID-5 RV). 5. Interested in using either Repetitive Transcranial Magnetic Stimulation (rTMS) or nicotine replacement therapy as a smoking cessation treatment. 6. Intending on quitting smoking within the next 30 days. Exclusion Criteria: Patient Participants: 1. Contraindication to rTMS according to the TMS Adult Safety Screen (TASS) and PI review. 2. Have any intracranial implant (e.g., aneurysm clips) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed. 3. Pregnant or intending to be pregnant during the study. 4. A history of a primary seizure disorder, seizure associated with an intracranial lesion, recurrent seizures related to substance intoxication or withdrawal or recent seizure within the last 6 months. 5. Space occupying intracranial lesion. 6. Any generalized skin disorders precluding the use of the nicotine patch. 7. Any known hypersensitivity or allergies to the nicotine patch. 8. Any known life-threatening arrhythmias or severe/worsening angina pectoris. 9. Within two weeks of experiencing a myocardial infarction or cerebral vascular accident. 10. Currently using or has used nicotine replacement therapy within the past two weeks. 11. Diagnosed with a terminal illness 12. Current regular use of e-cigarettes or other vaping devices containing nicotine and not willing to stop using these devices for the duration of the study. 13. Acutely unstable medical, psychiatric, or substance use disorder comorbidity with safety concerns at the discretion of the PI or study physician. 14. Previous treatment with rTMS for smoking cessation 15. Treatment with nicotine replacement therapy anytime within the last 1 month
๐Ÿ’Š

What it tests

  • Brainsway H4 deep Repetitive Transcranial Magnetic Stimulation (rTMS) coil
  • Nicotine replacement
๐Ÿ“

Where

1 site
Centre for Addiction and Mental Health
Toronto, Canada
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy